The Cancer Chemotherapy Handbook, 6th Edition
Please note that due to a system merger our fulfilment system will be down beginning September 22nd with an anticipated date to begin shipping orders October 10th. We would like to apologize for any inconvenience by offering you a special 20% discount on select products. Please use Promotional Code 12760. Click here for promotion details.
Here's a comprehensive, yet compact and practical guide to the care and chemotherapeutic treatment of cancer patients. It encompasses all major chemotherapeutic agents and combinations, investigational and newly approved drugs, and describes their mechanisms of action, indications, metabolism, dose, administration, toxicity, and drug interactions and incompatibilities. The 6th Edition includes more than 75 new drug regiments as well as a new chapter on medication errors and safety.Table of Contents
New to This Edition
- Updates and revises all chapters.
- Describes 100 new chemotherapeutic drugs.
- Features a new chapter on medication errors and safety.
- Presents new information on monoclonal antibodies.
- Uses a multidisciplinary approach that reflects the work of the entire chemotherapeutic team.
- Contains essential information on all chemotherapeutic agents and "cocktail" combinations.
- Covers high-dose chemotherapy with stem cell support, recognizing the rapid progress of stem cell therapy and highlighting potentially significant risks.
- Lists chemotherapeutic drugs and biological response modifiers alphabetically, and arranges cancer treatment protocols by cancer type.
- Provides the most comprehensive list of chemotherapeutic drugs available.
The Fischer handbook offers a more user-friendly, clearer presentation and an important chapter on the principles and applications of clinical trials.
Cancerworld - May/June 2005
By David S. Fischer, MD, Clinical Professor of Medicine, Yale University School of Medicine, New Haven, CT; M. Tish Knobf, RN, PhD, Associate Professor, Oncology Nursing, Yale University School of Nursing, New Haven, CT; Henry Durivage, PharmD, Director of Clinical Affairs, Theradex Systems, Inc, Princeton, NJ; and Nancy Beaulieu, PharmD, Staff Affiliate, Medical Oncology, Yale University School of Medicine, New Haven, CT